An announcement from NetraMark Holdings ( (TSE:AIAI) ) is now available.
NetraMark Holdings announced the presentation of new AI-driven clinical trial tools at the ISCTM Annual Meeting, showcasing their potential to transform CNS clinical trials by improving patient stratification and predictive accuracy. Their novel machine learning approach demonstrated a significant improvement in model accuracy for major depressive disorder and schizophrenia studies, promising more effective treatment identification.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in generative AI software, specializing in clinical trial analytics. The company’s primary focus is on enhancing predictive modeling and patient stratification in psychiatric clinical trials, demonstrating a strong market focus on improving outcomes for central nervous system disorders.
YTD Price Performance: 7.43%
Average Trading Volume: 8,232
Technical Sentiment Consensus Rating: Sell
For an in-depth examination of AIAI stock, go to TipRanks’ Stock Analysis page.